HER2 Targeted Therapy For Early Stage Breast Cancer: A Comprehensive Review

Another area of major change is in the area of targeted treatments for breast cancer. Her2+ breast cancers account for 1 in 5 breast cancers diagnosed in the United States. 20 years ago it was considered one of the bad cancers to get. But in 1998, a targeted medication called Herceptin became available and over the past 20 years has revolutionized the treatment of Her2+ cancers. With the advent of Herceptin, and now additional Her2 targeted drugs, Her2+ breast cancers are now very curable and treatable. A recent study showed that the use of Herceptin with chemotherapy for early stage Her2+ breast cancer has a 98% disease free survival at 3 years.

Source : https://www.idahopress.com/community/health/advances-in-breast-cancer-a-look-back-over-the-past/article_e18831c2-8227-53e1-bf28-39dee2e4affa.html

Advances in breast cancer: a look back over the past 20 years
HER2-Targeted Therapy for Early-Stage Breast Cancer: A Comprehensive Review
MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
Roche's Kadcyla Approval Will Have A Big Impact On Breast Cancer Patients
New ASCO Guide for Adjuvant Therapy in Early Breast Cancer
NCCN Refines Guidelines for Breast Cancer Care
A Closer Look at HER2-Targeted Therapies
Treatment of HER2-positive breast cancer: current status and future perspectives
Clinical trial seeks to help HER2-positive breast cancer patients
Dr Adam Brufsky: Choosing a Therapy for Breast Cancer Patients